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Introduction: The evaluation of patients with hyperhidrosis (HH) can be ac-
complished, among other ways, through questionnaires and scales. The Hyper-
hidrosis Disease Severity Scale (HDSS) has been used as a simple and quick tool 
to perform this evaluation. Although HDSS has been well established in several 
languages, it has not been translated into Portuguese, restricting its specific use 
for Brazilian patients. The aim of this study was to translate HDSS into Portu-
guese and validate it in a sample of Brazilian subjects.
Method: 290 Brazilian patients (69% women, with a mean age of 28.7±9.6 years 
and BMI 22.4±3.9 kg/m2) diagnosed with HH were evaluated using HDSS, Qual-
ity of Life Questionnaire (QLQ) and Sweating Evolution Questionnaire (SEQ) 
before and after a five-week oxybutynin treatment. Regarding validation, an 
association between HDSS results and two other questionnaires was performed. 
To analyze HDSS sensitivity, evaluation of effects pre- and post-treatment with 
oxybutynin was conducted. Furthermore, HDSS reproducibility was analyzed 
in a subsample in which the scale was applied again after 7 days of the first fol-
low-up appointment.
Results: There was statistical correlation between HDSS and QLQ and between 
HDSS and SEQ before treatment and after 5 weeks. Additionally, HDSS was 
reproducible and sensitive to clinical changes after the treatment period.
Conclusion: The Portuguese version of HDSS has been validated and shown to 
be reproducible in a Brazilian sample. Therefore it can be used as a tool to im-
prove medical assistance in patients with HH.
Keywords: hyperhidrosis, scales, questionnaires, translations, validation studies.
introduction  
Hyperhidrosis (HH) is a somatic disorder characterized 
by local excess sweating in specific regions of the body 
due to hyperfunction of eccrine sweat glands, often re-
lated to an emotional distress.1
There are several ways to diagnose and predict out-
comes of HH. In general, objective measures such as tran-
sepidermal water loss measurement are used to estimate 
the amount of sweat of each suspected site affected by 
HH. However, this approach is expensive and limited by 
its daily-based measures,2,3 resulting from measurements 
acquired at a particular time of the day and not allowing 
the analysis of sweating during longer periods.
Hence, questionnaires and scales have been developed 
to evaluate HH.4 The main advantages of their use include 
low cost, simplicity, potential self-filling and large-scale 
application.5 Recently, the Hyperhidrosis Disease Sever-
ity Scale (HDSS – International Hyperhidrosis Society®) 
was developed as a quick method,6 since it presents only 
one question with four options of answers related to the 
implications to patient’s daily routine and the degree of 
tolerance to the symptoms. The advantage of this scale 
is that its only question is simple and easy to respond, 
reducing the number of errors and optimizing medical 
evaluation.
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Despite its global acceptance, HDSS has not been 
validated or translated into Portuguese, preventing its use 
in Brazil. Thus, the aim of this project was to translate and 
validate the Portuguese version of the HDSS, in order to 
use it as an important scale in Brazilian patients with HH.
Method  
Sample  
A convenience sample of 290 patients of both genders was 
recruited to this study. After a clear explanation of all pro-
cedures, those who agreed to participate in the research 
protocol signed a consent form. This study was approved 
by the Local Research Ethics Committee (Approval number 
at Plataforma Brasil: CAAE40512414.7.0000.0071). Inclu-
sion criteria comprised individuals at the age of 18 years 
or older with a clinical diagnosis of palmar, axillary, or any 
association of these two forms of HH. All the patients in-
cluded in the study had the palmar or axillary form of HH, 
or an association of both. Patients with compensatory 
sweating were excluded.
Study design  
After translation and back-translation, HDSS was applied 
before and after 5 weeks of treatment with oxybutynin. 
All patients followed the same protocol. Oxybutynin was 
taken in progressively higher doses: starting at 2.5 mg 
once daily, which was increased to twice daily after one 
week, and 5 mg twice daily at the third week. If necessary 
and tolerated, for patients weighing more than 40 kg, the 
total dose was increased to 20 mg/day. For patients weigh-
ing less than 40 kg, the total dose was not increased after 
3 weeks. 
In addition, the Quality of Life Questionnaire (QLQ) 
and the Sweating Evolution Questionnaire (SEQ) were 
applied. In order to analyze the reproducibility of the 
Portuguese version of HDSS, a subsample was recruited 
and reassessed using HDSS 7 days after the first appoint-
ment.
Hyperhidrosis Disease Severity Scale translation  
A native qualified Portuguese-speaking professional, spe-
cialized in technical translations and fluent in English, 
as well as experienced with medical literature, carried out 
the translation. Following the translation there was a 
trial phase where the understanding of the Portuguese 
version of HDSS scale was checked out by an additional 
sample of 40 patients with HH. They outlined major areas 
for improvement to make it more coherent and under-
standable. Later, experts evaluated HDSS to make sure 
its content included all the necessary elements for satis-
factory evaluation of the disease, in the light of Brazilian 
culture, and included the modifications suggested by the 
patients. After applicable and convenient changes, the 
“new” HDSS scale (Portuguese version) was back trans-
lated into English by another professional with the same 
skills, who had no access to the original scale (in English). 
The “new” HDSS scale (in Portuguese) and its classical 
version in English were compared, and discrepancies were 
corrected, preserving semantic and idiomatic equiva-
lences to compose a straightforward scale (Figure 1).
Hyperhidrosis Disease Severity Scale  
HDSS consists of a simple and straightforward question 
with four available answers (grades 1 through 4) related 
to patient tolerance of HH symptoms and the negative 
implications of body perspiration to their everyday lives. 
Patients are asked to indicate a HDSS score specifically 
for each site of HH.
In our study, we evaluated only palmar and axillary 
symptoms, and patients could indicate different site-spe-
cific HDSS scores, according to the impairment of quality 
of life caused by excessive sweating in each area. Patients 
answered this scale twice: in the first appointment (before 
starting treatment, week 0), and in the end of the five-week 
treatment (week 5). Answer graded as 1 meant no percep-
tible sweating and lack of interference in everyday life; grade 
2, tolerable sweating with seldom interference in everyday 
life; grade 3, little tolerable sweating with frequent interfer-
ence in everyday life, and grade 4, intolerable sweating with 
constant interference in everyday life.
FIGURE 1 Translation of Hyperhidrosis Disease Severity Scale 
(HDSS) into Portuguese.
Escala de gravidade da hiperidrose 
O meu suor:
1
Não é perceptível e
nunca
interfere com minhas atividades do dia a dia
2
É tolerável, mas
às vezes
interfere com minhas atividades do dia a dia
3
É pouco tolerável e
frequentemente
interfere com minhas atividades do dia a dia
4
É intolerável e
sempre
interfere com minhas atividades do dia a dia
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For data purposes, the analysis yielded a delta of im-
provement on HDSS. For example: Pre-treatment (week 
0) minus post-treatment (week 5) = delta. Thus, delta = 0 
or 1 was considered no improvement; delta = 2 was con-
sidered slight improvement, and delta = 3 was considered 
good improvement. For example, if the patient reported 
at the first appointment HDSS = 4 (intolerable sweating 
with high interference in everyday life) and after 5 weeks 
reported HDSS = 1 (not noticeable sweating and lack of 
interference in routine activities), delta was 3 (good im-
provement).
Quality of Life Questionnaire  
The QLQ is a 20-question form divided into five domains. 
Each of these domains or group of actions has five levels 
of answers based on tables that admit a single response. 
The sum of all points varies between 20 and 100. Quality 
of life was rated as: much better (20-35), slightly better 
(36-51), and no improvement (52-100).7,8
Sweating Evolution Questionnaire  
The SEQ is based on a scale from 0 to 10, in which 0 means 
no sweating improvement and 10 refers to total resolution 
of symptoms. It was applied 5 weeks after treatment in the 
follow-up medical appointment. Patients chose a score from 
0 to 10, according to the degree of symptomatic improve-
ment. Results were classified as: no improvement (0-4), slight 
improvement (5-7) and great improvement (8-10).9-13
Statistical analysis  
To determine an association between the HDSS respons-
es and the other two questionnaires (QLQ and SEQ), 
chi-square test was used. Kappa coefficient was performed 
to examine the reproducibility of HDSS scale. Finally, 
sensitivity to treatment was calculated using the Wil-
coxon test. Statistical analysis was performed using SPSS 
software (v. 17, SPSS Inc. Chicago, IL). P-values lesser than 
0.05 were considered statistically significant.
results  
Patients’ demographics are summarized in Table 1. Re-
garding general characteristics of the sample population, 
69% were female. Patients were young, with an average 
age of 28.7 years [standard deviation (SD) 9.6; range 18-
60]. Additionally, mean body mass index (BMI) was 22.4 
kg/m2 (SD 3.9; range 10.6-35.4).
Table 2 shows the association between responses ob-
tained with HDSS and QLQ. There was a significant as-
sociation between the responses obtained with HDSS and 
QLQ in the palmar group (p<0.001), and 94% of patients 
who reported good improvement in HDSS were more 
likely to report much better results with QLQ. There was 
no significant correlation between HDSS and QLQ in the 
axillary group.
Table 3 shows the association between responses ob-
tained with HDSS and SEQ. There was a significant as-
sociation between the responses obtained with HDSS and 
SEQ in both axillary (p<0.01) and palmar groups (p<0.01). 
As in SEQ, 92 and 96% of patients who reported good 
improvement with HDSS (delta = 3) in the axillary and 
palmar groups, respectively, showed to be more likely to 
report great improvement with SEQ (in both regions).
In a subsample of 34 patients, we conducted HDSS 
test-retest after a seven-day interval for patients with 
axillary HH. This resulted in a kappa index = 0.65 (0.29 
to 0.97, CI 95%), showing moderate levels of agreement. 
In this group, 94% of patients reported the same values 
at the first appointment and after a seven-day follow-up. 
In addition, we carried out HDSS test-retest in a subsa-
mple of 58 patients with palmar HH, with a resulting 
kappa index of 0.84 (0.61 to 1.00, CI 95%), showing sub-
stantial degree of agreement. In this group, 96% of patients 
reported the same values at the first appointment and 
after 7 days.
Finally, to evaluate the degree of change in the HDSS 
scale, we analyzed the patients’ responses in the pre-treat-
ment period and after 5 weeks of oxybutynin intake. Wil-
coxon values showed differences in median values of HDSS 
pre- and post-treatment, and turned out to be significant 
for both groups, palmar (z=-11.1 and p<0.01) and axillary 
(z=-8.7 and p<0.01), respectively.
discussion  
The aim of this study was to translate and validate the 
HDSS for Brazilian patients with HH. Results showed that 
its Portuguese version has good reliability, reproducibility, 
and is sensitive to changes after clinical treatment, therefore 
being useful for management of patients with HH.
Currently, there are several ways to evaluate and pre-
dict HH prognosis. In our institution, patient follow-up 
is now performed using two independent questionnaires: 
one assesses the degree of improvement in sweating after 
treatment, and another evaluates the changes in quality 
of life before and after treatment. These two have been 
used in different studies,7,8 but we believe that the HDSS 
adds value to medical assistance since it is objective and 
simple, providing a good evaluation of  degree of sweating 
in different body parts. Moreover, HDSS can be used by 
non-specialists, as a referral triage tool for patients with 
HH.
Varella aYM et al.
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TABLE 1 Demographic characteristics of patients.
Palmar Axillary Total
Gender Female 70% 68% 69%
Male 30% 32% 31%
Age
(years)
Average±SD 26.5±9.0 31.2±9.8 28.7±9.6
Range 18-59 18-60 18-60
BMI 
(kg/m2)
Average±SD 22.4±3.9 23.8±3.8 22.4±3.9
Range 10.6-35.0 13.4-35.4 10.6-35.4
SD: standard deviation; BMI: body mass index.
TABLE 2 Association between responses from Hyperhidrosis Disease Severity Scale (HDSS) and Quality of Life 
Questionnaire for patients with axillary (N=115) and palmar hyperhidrosis (N=175).
Quality of Life Questionnaire 
HDSS (axillary) No improvement Slightly better Much better Total
No improvement 21% 45% 33% 100%
Slight improvement 7% 44% 49% 100%
Good improvement 0% 50% 50% 100%
HDSS (palmar)
No improvement 22% 43% 45% 100%
Slight improvement 3% 40% 57% 100%
Good improvement 0% 6% 94% 100%
TABLE 3 Association between responses from Hyperhidrosis Disease Severity Scale (HDSS) and Sweating Evolution 
Questionnaire for patients with axillary (N=115) and palmar hyperhidrosis (N=175).
Sweating Evolution Questionnaire 
HDSS (axillary) No improvement Slight improvement Great improvement Total
No improvement 28% 25% 47% 100%
Slight improvement 0% 11% 89% 100%
Good improvement 8% 0% 92% 100%
HDSS (palmar)
No improvement 28% 25% 47% 100%
Slight improvement 0% 11% 89% 100%
Good improvement 0% 6% 94% 100%
To assess the reliability of the Portuguese version of 
the HDSS, an association was made between its results 
and those obtained through QLQ and SEQ. By compar-
ing data from HDSS and SEQ, we found significant as-
sociation between the palmar and axillary groups.
On the other hand, comparing responses obtained 
with HDSS and QLQ, we verified that there was a signif-
icant association only in patients with palmar HH. One 
possible cause for the absence of association in patients 
with axillary HH is that QLQ is based on questions relat-
ed to issues regarding excessive sweating in hands, which 
affects the evaluation of patients with primary axillary 
HH. Because SEQ is wider on its assessment with an ex-
tensive evaluation of other body parts, a positive associ-
ation between HDSS and SEQ could be due to this fact.
More than association analyses, a comprehensive 
investigation to evaluate the degree of change in the HDSS 
scale pre- and post-oxybutynin treatment was performed. 
This study showed statistical evidence that both palmar 
and axillary HH improved in the HDSS, expressing its 
sensitivity to demonstrate changes in patients’ symptoms 
over time under treatment.
Finally, we conducted in a subsample a test-retest 7 
days after the first follow-up. Results showed satisfactory 
reproducibility rates, with 94 and 96% of axillary and 
palmar HH patients, respectively, reporting the same 
HDSS values when comparing first and second queries.
Our study has some limitations. This Portuguese 
version of the HDSS was only applied to patients with 
palmar or axillary HH and, therefore, the results cannot 
be generalized to patients with symptoms in other areas. 
Moreover, we only analyzed the association between HDSS 
and subjective methods to evaluate HH. Further studies 
regarding the correlation between HDSS and objective 
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evaluations of HH (e.g. sudorometer) are required to 
validate these results.
As can be seen from our results, we believe that the 
translation and validation process of HDSS into Portu-
guese was successful. It showed significant statistical 
correlation with other questionnaires (construct valida-
tion), good reproducibility rates and sensitivity to chang-
es after clinical treatment. Thus, we can confidently state 
that the Portuguese version of the HDSS can be used in 
clinical practice to evaluate the degree of sweating and 
patient outcomes, as well as manage the treatment of 
patients with HH, in both palmar and axillary HH.
conclusion  
The Portuguese version of the HDSS showed reliability 
and reproducibility in a Brazilian sample and can be used 
as healthcare tool in patients with HH.
resuMo 
 
Tradução e validação da Hyperhidrosis Disease Severity 
Scale
Objetivo: a avaliação de pacientes com hiperidrose (HH) 
pode ser realizada, entre outras maneiras, por questioná-
rios e escalas. O Hyperhidrosis Disease Severity Scale 
(HDSS) tem sido utilizado como uma forma simples e 
rápida. Embora o HDSS seja utilizado em outros idiomas, 
ainda não foi traduzido para o português, limitando sua 
utilização em pacientes brasileiros. O objetivo deste estu-
do foi traduzir o HDSS para o português e validá-lo em 
uma amostra brasileira.
Método: duzentos e noventa (290) pacientes brasileiros 
(69% mulheres, idade média de 28,7±9,6 anos e IMC mé-
dio de 22,4±3.9 kg/m2) com HH foram avaliados pelo 
HDSS, pelo Questionário de Qualidade de Vida (QQV) e 
pelo Questionário de Evolução da Sudorese (QES) antes 
e após 5 semanas de tratamento com oxibutinina. Para a 
validação de constructo do HDSS, foi realizada a associa-
ção entre seus resultados com os dos outros dois ques-
tionários. Para analisar a sua sensibilidade, foi realizada 
a análise do efeito pré e pós-tratamento com oxibutinina. 
Além disso, foi analisada a sua reprodutibilidade em uma 
subamostra, na qual a escala foi aplicada novamente após 
7 dias da primeira consulta.
Resultados: observamos correlação estatística entre o 
HDSS e o QQV e entre o HDSS e o QES antes do trata-
mento e após 5 semanas. O HDSS demonstrou ser repro-
dutível e sensível em relação ao efeito do tratamento.
Conclusão: a versão em português da escala HDSS apre-
sentou validade e reprodutibilidade em amostra brasilei-
ra e pode ser utilizada como instrumento na assistência 
à saúde de pacientes com HH.
Palavras-chave: hiperidrose, escalas, questionários, 
traduções, estudos de validação. 
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